CDMOs offering Autologous Cell Therapy Manufacturing with Cell Therapy
19 published
19 published CDMOs match Autologous Cell Therapy Manufacturing and Cell Therapy.
Locations in this set include United States, China, Japan, United Kingdom, Belgium, and Canada.
Capabilities that show up most often in this set: Allogeneic Cell Therapy Manufacturing, Cell Therapy Manufacturing, Process Development, CMC Analytical Development, and CMC Regulatory Submission Support.
Matching companies
Bramble BioBramble Bio specializes in cGMP manufacturing and process development for cell therapy ATIMPs, including autologous and allogeneic therapies, with 20+ years of expertise, 16 Grade B cleanrooms, and support for over 8,000 dosed patients across 46 countries.
CatalentGlobal CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
Cell TherapiesGMP contract manufacturer of autologous and allogeneic cell therapies from first-in-human trials through commercial supply, with two decades of experience in CAR-T, mesenchymal stromal cells, TILs, and pluripotent stem cell derivatives. Offers end-to-end cold chain management, process development, quality control analytics, and regulatory consulting across Australia and Asia-Pacific.
Cell and Gene Therapy CatapultUK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.
Cell-EasyCell-Easy is a CDMO specializing in development and GMP manufacturing of cell therapies, with expertise across T cells, NK cells, MSCs, and iPSCs. The company has manufactured over 1,000 clinical doses and supports 50+ development programs from process optimization through regulatory compliance.
Cellab CDMOCell and gene therapy CDMO providing cell banking, GMP manufacturing, cryopreservation and EU QP batch release for clinical-stage ATMPs. Operates a 1,000 m² facility with four Grade B and one Grade C cleanroom plus an AABB-accredited cell bank.
CellaresCellares operates a global network of Smart Factories delivering integrated development and manufacturing (IDMO) services for cell therapies, with proprietary Cell Shuttle® and Cell Q™ platforms enabling cGMP-compliant, automated manufacturing and quality control at clinical and commercial scale.
Cellipont BioservicesCellipont Bioservices is a cell therapy CDMO offering end-to-end development, analytical, and cGMP manufacturing services for autologous, allogeneic, CAR-T, and iPSC-derived therapies from preclinical through commercial stages.
Enable Biotech LtdEnable Biotech provides clinical GMP manufacturing for cell therapies, exosome therapies, and gene therapies, with SwissMedic accreditation pending for gene therapy operations as of summer 2024.- HillgeneHillgene is a leading CDMO provider specializing in cell therapy manufacturing, offering end-to-end solutions for CAR-T, TCR-T, CAR-NK, and UCAR-T cell therapies with GMP facilities in Suzhou and Belgium.
Minaris Advanced TherapiesPure-play cell and gene therapy CDMO with over 25 years of GMP manufacturing, process development, and biosafety testing expertise. Serves advanced therapy innovators globally from early stage through commercialization.
National ResilienceEnd-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
OmniabioOmniaBio is a cell and gene therapy CDMO specializing in process development, analytical development, and GMP manufacturing for lentiviral vectors, iPSCs, and immune cell-based therapies. The company operates a 120,000 sq ft facility in Hamilton, Ontario, integrating AI, automation, and robotics to deliver scalable manufacturing from preclinical to commercial stages.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
PluriFull-service CDMO specializing in cell therapy manufacturing with GMP facilities, proprietary packed-bed expansion technology, and regulatory approvals from FDA, EMA, PMDA, and other key agencies for clinical-stage production.
Porton AdvancedEnd-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.
RoslinCTRoslinCT is a cell and gene therapy CDMO offering cGMP iPSC banking, process and analytical development, and clinical and commercial manufacturing for autologous and allogeneic programs.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
eXmoor PharmaIntegrated cell and gene therapy CDMO with 20+ years of consultancy expertise, offering end-to-end CMC support from early-phase strategy through GMP manufacturing across viral vectors, autologous/allogeneic cell therapies, and RNA technologies.
Markdown mirror: /explore/autologous-cell-therapy-manufacturing/cell-therapy.md